Is compounded PT-141 injection the same as Vyleesi?

No. Compounded PT-141 injection and Vyleesi contain the same active ingredient, bremelanotide, but they are not the same finished medication. Vyleesi is an FDA-approved, prefilled autoinjector. Compounded PT-141 is a separately prepared prescription, not an FDA-approved generic version of Vyleesi.

That distinction does not mean the ingredient is unrelated or unstudied. It means the research, dose, delivery device and instructions need to be understood in context.

If you're comparing the two because you miss wanting sex, the useful questions go beyond the name: What benefit are we aiming for? Why this preparation? And what will I actually need to do when it arrives?

Same ingredient. Different prescription.

PT-141 is another name used for bremelanotide. It is non-hormonal and acts on melanocortin receptors, including receptors in the brain. It is not testosterone or estrogen replacement, and it is not the same kind of treatment as an erection pill.

The Vyleesi prescribing information describes a single-dose autoinjector containing 1.75 mg in 0.3 mL. MintRx's compounded PT-141 injection offering is a 20 mg powder vial that must be mixed according to its pharmacy instructions before use. The 20 mg describes the vial's total content, not the amount to inject at once.

Those numbers describe different things. A vial containing more total medication is not automatically a stronger dose, a better treatment or an interchangeable substitute.

What changes in practice?

What did Vyleesi's studies show?

Vyleesi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. That means low desire developed after a period without the problem, occurs across situations, and causes marked distress or interpersonal difficulty. Under its label, the problem is not explained by another medical or psychiatric condition, relationship problems or the effects of a medication or drug.

In the two randomized RECONNECT trials, premenopausal women with HSDD received bremelanotide 1.75 mg by subcutaneous injection or placebo as needed over 24 weeks. Bremelanotide improved questionnaire measures of sexual desire and distress about low desire compared with placebo. The trials did not show a statistically significant improvement over placebo in the number of satisfying sexual events, a secondary outcome.

That is useful evidence for the studied treatment and population. It is not a head-to-head comparison showing that a particular compounded vial performs the same as Vyleesi.

Vyleesi is not indicated for men, postmenopausal women or sexual performance enhancement. Its approval and these trials do not answer every question about bremelanotide use outside that population. A separate prescribing decision does not expand the FDA-approved indication.

Why might a compounded prescription be considered?

Compounding has a role when a patient's medical need cannot be met by an FDA-approved medication. The important question is what need the proposed preparation addresses for you, rather than assuming compounded means either better or worse for every person.

FDA's explanation of compounding distinguishes a compounded prescription from an approved generic. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing.

Ask your prescriber why the compounded preparation is being considered in your situation. Then ask the dispensing pharmacist to explain the medication you will receive:

• What is the concentration after preparation, and how do I measure my prescribed amount?
• Does the vial need mixing, and which written instructions apply?
• How should it be stored before and after mixing?
• When must I discard it, even if medication remains?
• Who should I contact if the label, supplies or instructions do not match?

For MintRx's current PT-141 injection offering, the powder is stored at room temperature before mixing. After mixing, it is refrigerated and discarded 28 days after reconstitution or by the pharmacy-labeled beyond-use date, whichever comes first. Follow the instructions on your own dispensed prescription.

Write down the mixing date. A vial with liquid left in it is not necessarily a vial you should keep using. If anything about preparation or measurement is unclear, ask before injecting.

Does compounding change the safety questions?

Different packaging does not remove concerns associated with bremelanotide. Vyleesi's safety information is an important reference, although it does not establish the complete safety profile or side-effect rates of a particular compounded preparation.

Before treatment, review these points with your prescriber:

• Blood pressure and heart health. Vyleesi is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. It can temporarily raise blood pressure and lower heart rate.
• Tolerability. Nausea, flushing, headache, vomiting and injection-site reactions are reported with Vyleesi. If symptoms are persistent or troublesome, contact the clinical team rather than pushing through them or adjusting the prescription yourself.
• Pigment changes. The label warns about darkening of areas of skin or gums, which may persist after stopping.
• Other medications. Bremelanotide can slow stomach emptying and affect absorption of oral medicines. The Vyleesi label specifically advises avoiding use with oral naltrexone intended to treat alcohol or opioid addiction because reduced exposure could cause treatment failure. Have the team review your medication list; do not stop another medication on your own.
• Pregnancy and other health history. Discuss pregnancy plans, possible pregnancy, breastfeeding, and kidney or liver disease. Vyleesi's label advises effective contraception and stopping treatment if pregnancy is suspected.

Ask what improvement you are looking for and when to review whether treatment is worth continuing. Benefits, tolerability and your actual experience all belong in that conversation.

Does this also apply to PT-141 nasal spray?

PT-141 nasal spray contains the same active ingredient, but uses a different route. Vyleesi's approval is for its injectable product, not a nasal preparation.

Injection and nasal instructions are not interchangeable. The amount absorbed, the preparation and the directions can differ. Do not turn an injection amount into a number of sprays or switch formats on your own.

If you are considering a change, explain what you want to improve, whether that is the administration process, your response or tolerability. The comparison should address that question, not just whether both labels say PT-141.

What can a pharmacist help you sort out?

You should not have to translate a product listing into medication instructions on your own. MintRx pharmacist support can help you understand the difference between the vial's total content, the concentration and your prescribed amount, along with preparation, storage and follow-up questions.

Bring the label or a clear photo if you already have a prescription. If you've tried treatment, describe what changed, what did not and any unwanted effects. That is more useful than simply saying it worked or didn't work.

A licensed provider decides whether a prescription is appropriate; online intake does not guarantee approval. The dispensing pharmacy supplies the preparation-specific instructions. MintRx's guide to what happens after you start treatment online explains the care process, and the guide on when to call the pharmacy team helps you reach the right person.

Compare the prescription, not just the name

Bremelanotide is the connection between PT-141 and Vyleesi. The formulation, device, evidence and instructions are what keep them from being interchangeable products.

You do not need to sort out every medication detail before asking for help. Start with what you want to improve and bring any prescription you already use. Talk with a MintRx pharmacist about the questions you want answered before the next step.

Sources

• Vyleesi prescribing information, DailyMed
• Kingsberg and colleagues, “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials,” Obstetrics & Gynecology, 2019
• FDA, “Compounding and the FDA: Questions and Answers”